Abstract:Objective: To observe the efficacy and safety of CLAE intensive chemotherapy followed by allogeneic hematopoietic stem cell transplantation (allo-HSCT) in patients with relapsed/refractory acute leukemia (R/R AL). Methods: CLAE regimen [cladribine 5 mg/(m2·d), d 1-5; cytarabine 1.5 g/(m2·d), d 1-5; etoposide 100 mg/(m2·d), d 3-5] followed by allo-HSCT was used to treat 3 R/R AL patients. The patients received CLAE chemotherapy in relapsed or refractory status and underwent bone marrow puncture to judge myelodysplastic state. After an interval of 3 to 5 days, followed by preconditioning regimen for allo-HSCT [fludarabine 30 mg/(m2·d), d -7 to d -3; busulfan 0.8 mg/kg q6h, d -6 to d -3 or d -5 to d -2. If the bone marrow hyperplasia was not active and the blasts were less than 10%, busulfan should be used for 3 days. If the bone marrow hyperplasia was active and the blasts were more than 10%, busulfan should be used for 4 days]. Cyclosporin A, mycophenolate mofetil and short-term methotrexate were used for graft-versus-host disease (GVHD) prevention. After transplantation, the status of minimal residual disease (MRD) and bone marrow chimerism were regularly monitored in all 3 patients, and demethylation drugs or dasatinib were used to prevent recurrence 3 months after transplantation. Results: 2 patients with t(11;19) translocation and relapse/refractory acute myeloid leukemia recurred within 6 months after induction of remission, and received intensive chemotherapy with CLAE regimen followed by haploidentical allo-HSCT and unrelated donor allo-HSCT, respectively. The two patients both relapsed 6 months after transplantation, then achieved complete remission by donor lymphocyte infusion, interferon, interleukin-2 and other methods, and disease-free survival was 2 years after transplantation. The other patient was chronic myelogenous leukemia who developed acute lymphoblastic leukemia during oral administration of tyrosine kinase inhibitor, accompanied by T315I and E255K mutations in ABL1 kinase region and additional chromosomal abnormalities. After morphological remission by induction chemotherapy, central nervous system leukemia was complicated. Intensive chemotherapy with CLAE regimen followed by sibling allo-HSCT was performed in the positive state of MRD. The patient relapsed 3 months after transplantation, and achieved remission after chimeric antigen receptor T-cell (CAR-T) therapy, however, he died 5 months after transplantation because of severe cytokine release syndrome (CRS) and GVHD. Conclusion: CLAE regimen followed by allo-HSCT may be an effective salvage treatment option for R/R AL patients to prolong the overall survival.

Sequential cytokine induced killer cells therapy for acute myeloid leukemia after autologous peripheral blood stem cell transplantation

[Clinical Observation of Gleevec Combined with Myeloablative Allogeneic Stem Cells Transplantation in Treatment of Chronic Myeloid Leukemia].

Study on the treatment of auto-hematopoietic stem cell transplantation(Auto-HSCT) combined dendritic cells-cytokine-induced killer cells(DC-CIK cells) pulsed with freeze-thaw leukemia antigen infusions for acute myeloid leukemia

Dendritic-cell-activated and Cytokine-Induced Killer Cells Therapy for the Treatment of Acute Mylocytic Leukemia Previously Given Auto-Pbsct

The Efficacy of Chemotherapy in Combination with Auto-Cytokine-induced Killer Cells in Acute Leukemia

Sequential treatment combining cladribine-based re-induction, myeloablative allogeneic HSCT, and prophylactic donor lymphocyte infusion: a promising treatment for refractory acute myeloid leukemia

Effects of Dendritic Cell-Activated and Cytokine-Induced Killer Cell Therapy on 22 Children with Acute Myeloid Leukemia after Chemotherapy

Efficacy of autologous peripheral blood stem cell transplantation combined with DC-CIK cell infusion in treating acute leukemia

Changes of T lymphocyte subtypes in acute myeloid leukemia patients after auto-hematopoietic stem cell transplantation and treated with dendritic DC-CIK cells

Autologous hematopoietic stem cell transplantation followed by interleukin-2 for adult acute myeloid leukemia patients with favorable or intermediate risk after complete remission

Non-Ablative Chemotherapy Followed by HLA-Mismatched Allogeneic CD3+ T-Cells Infusion Causes An Augment of T-Cells With Mild CRS: A Multi-Centers Single-Arm Prospective Study on Elderly Acute Myeloid Leukemia and int-2/High Risk Myelodysplastic Syndrome Patients

Sequential intensified conditioning followed by graft-versus-leukemia induction could prevent relapse of refractory acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation

The Research Progress of the Use of Cytokine-induced-killer Cells in the Treatment for Acute Leukemia

Co-Cultured Dendritic Cell and Cytokine-Induced Killer Cell Adaptive Immunotherapy for Treating of Childhood Acute Leukemia

5 years of clinical DC-CIK/NK cells immunotherapy for acute myeloid leukemia - a summary.

[Efficacy of CLAE Chemotherapy Regimen Followed by Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Relapsed/Refractory Acute Leukemia]

Infusions of Recipient-Derived Cytokine-Induced Killer Cells of Donor Origin Eradicated Residual Disease in A Relapsed Leukemia Patient after Allo-Hematopoietic Stem Cell Transplantation

Using Auto Dendritic Cells Accompanied with CIK Plus Chemotherapy As Consolidation Treatment for 59 Patients with Acute Leukemia

Clinical observation of maintenance therapy with autologous cytokine-induced killer cells in patients with medium and advanced non-small cell lung cancer after first-line treatment

Expanded donor natural killer cell and IL-2, IL-15 treatment efficacy in allogeneic hematopoietic stem cell transplantation.

Curative Effect and Safety of Autologous Cytokine-induced Killer Cells Combined with Chemotherapy in the First Line Maintenance Treatment of Non-small Cell Lung Cancer